Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy

Sanjeev Luther, President & CEO of Ernexa Therapeutics

“We are honored that Ernexa has been selected for the Emerging Track at the 2026 Cell & Gene Meeting on the Mesa, and we look forward to sharing the progress we are making with ERNA-101.”

Sanjeev Luther, President & CEO of Ernexa Therapeutics

“We believe this recognition reflects the potential of our differentiated approach to cell therapy as we prepare to transition ERNA-101 toward the clinic.”

Sanjeev Luther, President & CEO of Ernexa Therapeutics

“Our strategy is focused on advancing one differentiated oncology candidate through a clear initial clinical pathway in platinum-resistant ovarian cancer, supported by a growing body of compelling preclinical evidence and independent validation of ERNA-101’s anti-tumor activity.”

Sanjeev Luther, President & CEO of Ernexa Therapeutics

“As we advance toward planned clinical entry, we believe our synthetic, off-the-shelf iMSC platform provides a differentiated foundation to establish clinical proof of concept in ovarian cancer and potentially expand ERNA-101 into broader oncology indications.”

Sanjeev Luther, President & CEO of Ernexa Therapeutics

“Most importantly, our focus remains on translating this strong preclinical foundation into a potential new treatment for patients who need better options.”